Patterson Companies (PDCO) Q3 Earnings: What's In Store?
Zacks Investment Research | Feb 25, 2018 08:27PM ET
Patterson Companies, Inc. (NASDAQ:PDCO) is scheduled to release third-quarter fiscal 2018 results on Mar 1. The company anticipates a decline in the Dental Supply segment — one of its major revenue components. While this can majorly dampen earnings, an expected improvement in Animal Segment operating income should drive results.
Notably, Patterson Companies reported adjusted earnings of 51 cents per share in second-quarter fiscal 2018, missing the Zacks Consensus Estimate of 54 cents. Net sales fell 2.3% from the year-ago quarter to $1.39 billion and lagged the Zacks Consensus Estimate of $1.42 billion.
Let us take a look at how things are shaping up before the release.
Dental-Supply Segment to Decline in Q3
The Zacks Consensus Estimate for the Dental Supply segment is $592 million for third-quarter fiscal 2018. This reflects a decline of almost 5.4% year over year.
The loss of exclusive distribution rights with Dentsply Sirona (NASDAQ:XRAY) forced the company to shift to a new enterprise resource planning system to efficiently manage inventory. However, the system is creating short-term challenges. Undoubtedly, the termination of the contract presents new opportunities for Patterson Companies to expand distribution platform to a wider range of product offerings. However, the company continues to witness heavy initial impact from the loss of this deal.
Patterson Companies, Inc. Price and EPS Surprise
The company’s decision to end exclusive distribution will affect results through fiscal 2018. In fact, dental segment sales have been sluggish over the last couple of quarters. Management has provided a dull guidance for the coming quarters as well.
In the last quarter, dental sales (40% of total sales) fell 8.4% at constant currency (cc) year over year to approximately $553.6 million. The downside was caused by lower sales of CEREC and digital technology products. Management expects headwinds in the technology-based equipment business to persist through fiscal 2018, adding to the company’s woes.
Other Factors at Play
Estimates & Guidance
For the third quarter, the Zacks Consensus Estimate for adjusted earnings is pegged at 51 cents, reflecting a decline of 12.1% year over year. Management anticipates headwinds in its technology equipment business to persist through fiscal 2018. This is primarily because of Patterson Companies’ initiatives to transit its sales model to an expanded technology product portfolio.
Further, the Zacks Consensus Estimate for revenues is pegged at $1.38 billion, showing a decline of 1.1% year over year.
In the last quarter, the company estimated adjusted earnings per share for fiscal 2018 in the range of $2.00-$2.10, way below the previous band of $2.25-$2.40. Patterson Companies expects deal amortization expenses of $25.3 million or 27 cents per share. The company projects integration and business restructuring expenses at $5.3 million or 6 cents per share.
Animal Health Segment
Animal Health is the second important contributor to revenues for Patterson Companies after the dental unit.
Steady growth in this unit is expected to be a long-term growth driver. Management expects solid margin improvement in the segment on the back of enhanced partnerships with product manufacturers and strong sales execution. The Zacks Consensus Estimate for operating income from the Animal Health unit is pegged at $30.9 million, reflecting an improvement of 33.1% from the last quarter.
However, the Zacks Consensus Estimate for net sales is $786 million, reflecting a decline of 4.6% year over year.
Our quantitative model does not show an earnings beat for Patterson Companies this quarter. This is because a stock needs to have a positive Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.